ClinicalTrials.gg
RecruitingNCT06209580Updated Sep 5, 2025

AMT-253 in Patients With Advanced Solid Tumours

A Phase 1/2 interventional study of AMT-253 for injection in Malignant Melanoma and Advanced Solid Tumors, sponsored by Multitude Therapeutics Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Multitude Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
60th of 189
96 · median 50
Started
2024
with 11 others
Phase 1/2
34 of 203
20 open now
Primary completion
2026-04
later than 28 of 94 live
Registered
144th of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 60th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2024, is one of 34 in phase 1/2, reaches primary completion later than 28 of the 94 other live ones, and was the 144th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

03

Conditions studied

  • Malignant Melanoma
  • Advanced Solid Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements.
  • 2. Patients with confirmed melanoma or other advanced solid tumor.
  • 3. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease (PD) during or after most recent , and for whom no further standard therapy is available, or who are intolerable to standard therapy.
  • 4. Patients must have at least one as per version 1.1.
  • 5. (ECOG) performance status of 0-1.
  • 6. ≥ 3 months.
  • 7. Patients must have adequate organ function
  • 8. Women of child bearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally for at least 12 consecutive months must agree to use two effective methods while on study treatment and for at least twelve weeks after the last dose of the IMP.
  • 9. WCBP must have a negative serum pregnancy test within 7 days prior to first dose of the IMP.
  • 10. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least twelve weeks after the last dose of the IMP.
  • 11. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP.
  • 12. Availability of tumor tissue sample at screening.

Exclusion criteria

Exclusion Criteria:

  • 1. Prior treatment with any agent that has the same target.
  • 2. Central nervous system (CNS) .
  • 3. Active or chronic skin disorder requiring systemic therapy.
  • 4. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.
  • 5. Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1.
  • 6. Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP.
  • 7. Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention.
  • 8. Significant cardiac disease, such as recent myocardial infarction or acute coronary syndromes, congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias.
  • 9. History of thromboembolic or cerebrovascular events, including , cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within six months prior to first dose of the IMP.
  • 10. Acute and/or bacterial, fungal or viral infection including (HBV), (HCV), known (HIV).
  • 11. Administration of a within 28 days prior to the administration of the first dose of the IMP.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm 1

    AMT-253 Dose Escalation

    Drug: AMT-253 for injection

  • Experimental
    Arm 2

    AMT-253 Dose Expansion

    Drug: AMT-253 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. DLTs

    Incidence of dose limiting toxicities

    Time frame: 21 days after first dose

  2. AEs

    Type, incidence and severity of Adverse Events

    Time frame: Up to 24 months

  3. SAEs

    Type, incidence and severity Serious Adverse Events (SAEs)

    Time frame: Up to 24 months

  4. ORR

    Overall response rate assessed by the investigator according to RECIST version 1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. Cmax

    aximum concentration (Cmax)

    Time frame: Up to 24 months

  2. Tmax

    time to peak drug concentration

    Time frame: Up to 24 months

  3. AUC

    Area Under the Curve

    Time frame: Up to 24 months

  4. t1/2

    terminal half-life of the ADC, total antibody and free payload

    Time frame: Up to 24 months

  5. ADAs

    Specification and quantification of anti-drug antibodies

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2026, 26 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's planned 26 months is below that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 17, 2024
StartActual
Jan 31, 2024
Primary completionEst.
Apr 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06209580
Lead sponsor
Multitude Therapeutics Inc.
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Jan 31, 2024
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 5, 2025

Study contacts

Minqi Guan
Contact
minqi.guan@multitudetherapeutics.com
86-15895820062

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMT-253

Start the discussion